[Skip to Navigation]
July 1966

Treatment of a Presumed Case of Sympathetic Ophthalmia With Methotrexate

Author Affiliations

Bethesda, Md
From the Ophthalmology Branch, National Institute of Neurological Diseases and Blindness, National Institutes of Health, Public Health Service, US Department of Health, Education and Welfare. Medicine Branch, Leukemia Service, National Cancer Institute, National Institutes of Health (Dr. Hersh). Dr. Hersh is presently at Stanford University Hospital, Department of Medicine, Palo Alto, Calif. Laboratory of Germfree Animal Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health (Dr. McMaster), Bethesda, Md.

Arch Ophthalmol. 1966;76(1):66-76. doi:10.1001/archopht.1966.03850010068014

Sympathetic ophthalmia usually occurs following a perforating injury to one eye. The mechanism of inducing the inflammatory process in the second eye is not clearly understood, but it is felt by many that "autosensitization" to uveal tissue plays an important role in the evolution of the disease process.1-16 Prior to the advent of corticosteroid therapy,17-20 this condition generally followed a chronic progressive course which resulted in irreparable damage to the eyes.

Within the past decade, a number of inflammatory conditions, presumed to have an underlying autoimmune mechanism, have been reported to respond favorably to certain antitumor agents.21 These antimetabolites are known to possess immunosuppressive and anti-inflammatory properties. One of these agents, methotrexate, has recently been shown to be effective in the therapy of several patients with steroid-resistant cyclitis.22

It is the purpose of this communication to report the successful treatment of a case of sympathetic ophthalmia

Add or change institution